UNMC Psychopharmacology Research Consortium

Alzheimer Disease Studies

The UNMC Department of Psychiatry is conducting a number of research studies using investigational medications for individuals with Alzheimer Disease.

Study 1: This study is evaluating a novel formulation of an FDA-approved medication, rivastigmine, for the treatment of persons with moderate to severe Alzheimer disease. This study compares a low-dose patch formulation of the drug to an investigational high-dose formulation.

Persons who are at least 50 years old, are in good general medical health, and have a reliable caregiver that can accompany them for appointments, may be eligible to participate.

For additional information, call 402-552-6005, or e-mail unmcprc@unmc.edu. This study is also listed on the clinicaltrials.gov website as: http://clinicaltrials.gov/ct2/show/NCT00948766

 Study 2: This is a study to evaluate whether the use of intravemous immune globulin (also called IGIV) can change the rate of memory decline and daily functioning in subjects with mild to moderate Alzheimer disease.

Person who are between the ages of 50 and 89, inclusive, are in general good health and who have a reliable caregiver may be eligible to participate.

For additional information, call 402-552-6005 or email unmcprc@unmc.edu This study is also listed on the clinicaltrials.gov website as: http://clinicaltrials.gov/ct2/show/NCT00818662

Future Studies:

We have also recently been selected to participate as a site in the NIH-sponsored, Alzheimer Disease Cooperative Study (ADCS) and expect to be able to update on potential studies sponsored by that group in the near future. For more information on the ADCS:http://www.adcs.org/

Click here for more information on studies